SFA Stock Overview
Produces, distributes, and exports pharmaceutical products in Europe, Bulgaria, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Sopharma AD Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | лв5.88 |
| 52 Week High | лв7.76 |
| 52 Week Low | лв5.30 |
| Beta | -0.040 |
| 11 Month Change | -0.68% |
| 3 Month Change | -2.65% |
| 1 Year Change | 8.49% |
| 33 Year Change | 68.97% |
| 5 Year Change | 79.27% |
| Change since IPO | -4.96% |
Recent News & Updates
Recent updates
Here's Why Sopharma AD (BUL:SFA) Can Manage Its Debt Responsibly
Jun 02
Sopharma AD (BUL:SFA) Has A Somewhat Strained Balance Sheet
Apr 09Here's Why We Think Sopharma AD (BUL:3JR) Is Well Worth Watching
Feb 20How Many Sopharma AD (BUL:3JR) Shares Do Institutions Own?
Feb 05Should You Rely On Sopharma AD's (BUL:3JR) Earnings Growth?
Jan 22Sopharma AD (BUL:3JR) Has A Somewhat Strained Balance Sheet
Jan 06
Sopharma AD (BUL:3JR) Share Prices Have Dropped 25% In The Last Three Years
Dec 22Should Sopharma AD (BUL:3JR) Be Part Of Your Dividend Portfolio?
Dec 07Are Investors Undervaluing Sopharma AD (BUL:3JR) By 29%?
Nov 19Should Sopharma AD (BUL:3JR) Be Part Of Your Dividend Portfolio?
Jul 07Shareholder Returns
| SFA | BG Pharmaceuticals | BG Market | |
|---|---|---|---|
| 7D | -0.7% | 0.5% | -0.3% |
| 1Y | 8.5% | 19.0% | 16.8% |
Return vs Industry: SFA underperformed the BG Pharmaceuticals industry which returned 19% over the past year.
Return vs Market: SFA underperformed the BG Market which returned 16.8% over the past year.
Price Volatility
| SFA volatility | |
|---|---|
| SFA Average Weekly Movement | 2.3% |
| Pharmaceuticals Industry Average Movement | 5.1% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in BG Market | 7.6% |
| 10% least volatile stocks in BG Market | 2.0% |
Stable Share Price: SFA has not had significant price volatility in the past 3 months.
Volatility Over Time: SFA's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1933 | 4,721 | Ognian Donev | www.sopharmagroup.com |
Sopharma AD produces, distributes, and exports pharmaceutical products in Europe, Bulgaria, and internationally. The company operates through Production of Pharmaceutical Products; Distribution of Pharmaceutical Products (Goods); and Others. It offers Carsil to treat liver disease; Tempalgin and Analgin, a painkiller; Tabex, drug used for smoking secession; Tribestan, drug used for stimulation of the male reproductive system; Broncholytin, which is used to suppress cough; Nivalin, used for diseases of the peripheral nervous system; Methylprednisolon, for severe allergies and life-threatening conditions; Vitamin C; Valeriana, used to reduce the stress; and medical devices, such as gauzes, compresses, and dressing.
Sopharma AD Fundamentals Summary
| SFA fundamental statistics | |
|---|---|
| Market cap | лв1.05b |
| Earnings (TTM) | лв92.66m |
| Revenue (TTM) | лв1.93b |
11.4x
P/E Ratio0.5x
P/S RatioIs SFA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SFA income statement (TTM) | |
|---|---|
| Revenue | лв1.93b |
| Cost of Revenue | лв1.51b |
| Gross Profit | лв426.62m |
| Other Expenses | лв333.96m |
| Earnings | лв92.66m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jan 30, 2025
| Earnings per share (EPS) | 0.52 |
| Gross Margin | 22.08% |
| Net Profit Margin | 4.80% |
| Debt/Equity Ratio | 36.3% |
How did SFA perform over the long term?
See historical performance and comparison